These findings emphasize the importance of tailoring treatment approaches in HD and other neurodegenerative diseases, recognizing the dynamic nature of disease progression and the complex interactions between immunomodulatory drugs and neurotrophin signaling pathways. This evidence concerns the gene BDNF and neurodegenerative disease.